Suppr超能文献

新型氯嘧啶系列作为激酶MSK1共价抑制剂的发现与表征

Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1.

作者信息

Hall Adrian, Abendroth Jan, Bolejack Madison J, Ceska Tom, Dell'Aiera Sylvie, Ellis Victoria, Fox David, François Cyril, Muruthi Muigai M, Prével Camille, Poullennec Karine, Romanov Sergei, Valade Anne, Vanbellinghen Alain, Yano Jason, Geraerts Martine

机构信息

UCB, Avenue de l'Industrie, Braine-L'Alleud 1420, Belgium.

UCB Seattle, 7869 NE Day Road West, Bainbridge Island, Washington 98110, United States.

出版信息

ACS Med Chem Lett. 2022 Jun 25;13(7):1099-1108. doi: 10.1021/acsmedchemlett.2c00134. eCollection 2022 Jul 14.

Abstract

We describe the identification and characterization of a series of covalent inhibitors of the C-terminal kinase domain (CTKD) of MSK1. The initial hit was identified via a high-throughput screening and represents a rare example of a covalent inhibitor which acts via an SAr reaction of a 2,5-dichloropyrimidine with a cysteine residue (Cys440). The covalent mechanism of action was supported by biochemical experiments and was confirmed by mass spectrometry. Ultimately, the displacement of the 2-chloro moiety was confirmed by crystallization of an inhibitor with the CTKD. We also disclose the crystal structures of three compounds from this series bound to the CTKD of MSK1, in addition to the crystal structures of two unrelated RSK2 covalent inhibitors bound to the CTKD of MSK1.

摘要

我们描述了一系列MSK1 C末端激酶结构域(CTKD)共价抑制剂的鉴定和特性。最初的命中化合物是通过高通量筛选鉴定出来的,它代表了一种罕见的共价抑制剂,通过2,5-二氯嘧啶与半胱氨酸残基(Cys440)的SAr反应起作用。生化实验支持了共价作用机制,并通过质谱法得到证实。最终,通过抑制剂与CTKD的结晶证实了2-氯部分的取代。除了两种与MSK1的CTKD结合的不相关RSK2共价抑制剂的晶体结构外,我们还披露了该系列中三种与MSK1的CTKD结合的化合物的晶体结构。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5644/9290008/09f6b9593dd4/ml2c00134_0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验